Enhancing Facial Nerve Neuroprotection and Regeneration Through Omega-3 Supplementation Following Vestibular Schwannoma Resection


About this study

The objectives of this study are to determine the impact of omega-3 supplementation on promoting facial nerve function recovery, and to determine the impact of omega-3 supplementation on Vestibular schwannoma (VS) tumor control.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • All patients 18 of age or greater.
  • VS on final pathology report.
  • Surgical intervention (RS, MF, TL, other).
  • Primary and revision cases included, including prior radiation.

Exclusion Criteria;

  • History of liver disease or abnormal liver function tests.
  • Diabetic patients with specific contraindication to omega-3 supplementation.
  • History of bleeding disorder, or recommended use of anticoagulation (not including anti-platelets or NSAIDs) during the treatment period.
  • Age less than 18 years.
  • Neurofibromatosis 1 or 2, or schwanomatosis disorders.
  • Non-VS pathology.
  • Patients already taking fish oil/omega-3 supplementation.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Michael Link, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer